Expeditious, biologically driven Pilot Libraries for File Enhancement

描述（由申请人提供）：本申请的目的是通过分子文库筛选网络（MLSCN）产生用于评价的中试规模文库。预计MLSCN筛选这些“设计师集合”的输出将有助于实现化学生物学的承诺，发掘高质量的小分子探针，以阐明未知功能蛋白质的生理作用。将靶向25个文库，包含25-80种表征的化合物（> 10 mg，>90%纯度）。为此，有效的文件增强需要多个功能领域的互补技能，因此，集体研究者提出了许多潜在的强大的医学相关协议，并在跨学术和工业环境的高通量药物化学和药物设计原则方面拥有深入的专业知识。合作各方的联合基础设施进一步加强了这一应用，可以随时使用最先进的筛查、结构生物学、高通量仪器和核心化学设施。将使用基于观察到的亚结构模式及其在PubChem和供应商数据库中的出现频率的分子相异性测量来评价支架独特性的概念。评价工具将包括但不限于标准多样子集和基于化学型的分层分析。选择的支架也将具有很强的生物理性，通常利用多个靶家族的关键分子识别基序。所有的脚手架都是独一无二的，被认为是结构上引人注目的。通过选择具有“高迭代效率潜力”的支架，将促进再供应和未来的SAR研究，1）提高药物化学家导航"假设-合成-筛选“循环的迭代速度，2）减少里程碑进展所需的迭代次数。本文详述的设计师库将为多种适应症的治疗进展提供机会。

DESCRIPTION (provided by applicant): The aim of this application is to produce pilot-scale libraries for evaluation via the Molecular Library Screening Network (MLSCN). It is expected that the output from MLSCN screening of these "designer collections" will help enable the promise of chemical biology, unearthing quality small molecule probes to elucidate physiological roles of proteins of unknown function. 25 libraries will be targeted, comprising 25-80 characterized compounds (>10mg, >90% pure). To this end, effective file enhancement requires complementary skill sets in multiple functional areas and as such, the collective investigators have proposed a multitude of potentially robust medicinally relevant protocols and possess a depth of expertise in high-throughput medicinal chemistry and drug design principles spanning both academic and industrial settings. The combined infrastructures of the collaborative parties further strengthen this application, with ready access to state of the art screening, structural biology, high-throughput instrumentation and core chemistry facilities. The notion of scaffold uniqueness will be evaluated using measurements of molecular dissimilarity based on observed substructure patterns and their frequency of occurrence in PubChem and vendor databases. Evaluation tools will include but are not limited to standard diverse subset and hierarchical chemotype-based analyses. Selected scaffolds will also have a strong biological rational, often taking advantage of crucial molecular recognition motifs of multiple target families. All scaffolds are unique and viewed as structurally compelling. Resupply and future SAR studies will be facilitated by selection of scaffolds possessing 'High Iterative Efficiency Potential' that 1) improve the iterative speed of the medicinal chemist navigating the 'hypothesis-synthesis-screening' loop and 2) reduce the number of required iterations for milestone progression. Designer libraries detailed herein will be presenting opportunities for therapeutic advances in multiple indications.